Welcome to our dedicated page for Biotricity SEC filings (Ticker: BTCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding FDA approval timelines, SaaS revenue recognition, and device trial costs inside Biotricity’s disclosures can feel overwhelming. Investors hunting for Biotricity insider trading Form 4 transactions or clues on reimbursement risk often wade through hundreds of pages. Stock Titan’s AI steps in, reading every line the moment it hits EDGAR and turning complexity into clarity.
In one dashboard, you’ll see the latest Biotricity quarterly earnings report 10-Q filing, real-time alerts for Biotricity Form 4 insider transactions real-time, and concise bullets that make Biotricity SEC filings explained simply. Our algorithm highlights segment revenue, R&D burn, and device approval milestones, then pairs each line item with Biotricity earnings report filing analysis you can act on. Rather than scanning footnotes, try understanding Biotricity SEC documents with AI that extracts risk-factor shifts and revenue guidance in seconds.
Need deeper dives? Compare Biotricity executive stock transactions Form 4 against pipeline announcements, read the Biotricity annual report 10-K simplified for long-term strategy, or check the Biotricity proxy statement executive compensation before voting. When headlines break, our alerts link directly to the Biotricity 8-K material events explained so you never miss trial results, financing updates, or partnership news. From detailed PDF downloads to interactive charts, Stock Titan delivers every filing type fast, with expert context that turns regulatory paperwork into actionable insight.
Biotricity Inc. is registering up to 44,117,647 shares of common stock in a primary offering at an assumed price of $0.34 per share. The medical technology company provides remote cardiac monitoring solutions such as its FDA-cleared Bioflux and Biotres devices, a direct-to-consumer Bioheart monitor, and the Biocare disease management platform, aiming to build recurring technology-fee revenue from cardiac diagnostics and chronic care.
The company has expanded sales to 33 U.S. states and is investing in AI-driven analytics, supported in part by a $238,703 NIH grant, while partnering with major cloud providers for its cardiac AI model. However, Biotricity carries substantial financial risk, including approximately $21.1 million of indebtedness as of March 31, 2023, a cash balance of about $308,460, an accumulated deficit of $140.97 million, and a working capital deficiency of about $18.08 million as of September 30, 2025.
Auditors have expressed substantial doubt about its ability to continue as a going concern, and the company faces a Nasdaq delisting process after failing to meet the $35 million market value of listed securities requirement. The S-1 outlines numerous risks, including heavy leverage, the need for additional capital, potential dilution from preferred stock and convertible notes, reimbursement and regulatory uncertainties, intense competition in cardiac monitoring, and volatility and limited liquidity in its common stock.
Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.
Ionic Ventures, LLC, Ionic Management, LLC, Brendan O’Neil, and Keith Coulston filed a Schedule 13G/A (Amendment No. 5) disclosing beneficial ownership of 2,926,171 shares of Biotricity Inc. (BTCY), representing 9.9% of the class, based on 26,567,769 shares outstanding as of August 13, 2025.
The position comprises 202,937 common shares and up to 2,723,234 shares issuable upon conversion of Series B Convertible Preferred Stock, subject to a 9.99% beneficial ownership limitation in the Certificate of Designations. As of September 30, 2025, up to 4,245,283 shares could be issuable within sixty days at an Alternate Conversion Price of $0.53, though portions are not deemed beneficially owned due to blocker and conversion notice limits. The reporting persons have shared voting and dispositive power over 2,926,171 shares and no sole power. They certify the holdings are not for the purpose of changing or influencing control.
Biotricity (BTCY) filed its quarterly report for the period ended September 30, 2025. The company grew revenue to $3,885,795 for the quarter (from $3,266,846) and $7,759,788 for the six months (from $6,468,589). Gross profit rose to $3,181,498 in the quarter, and Biotricity posted operating income of $273,819 compared with a prior-year operating loss. Net loss narrowed to $(690,913) for the quarter and $(1,362,890) year‑to‑date.
Liquidity remains tight with cash of $308,460 and total liabilities of $37,984,860, resulting in a stockholders’ deficit of $(33,412,378). Management disclosed a working capital deficiency of $18,077,790 and stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern. As of November 13, 2025, there were 27,797,711 common shares outstanding, plus 160,672 exchangeable shares, equivalent to 27,958,383 voting securities.
FAQ
What is the current stock price of Biotricity (BTCY)?
What is the market cap of Biotricity (BTCY)?
